Moderna Inc. closed at 145.13 USD, up 8.86%.

MRNA’s options market saw a single dominant large trade: a net-debit call combination totaling $11.90 million, all positioned at the $200.00 strike expiring on 2026-11-20. With the stock at $145.13, every leg is out of the money, signaling a premium-paid bullish structure rather than an income play. No bearish large-trade volume was recorded, creating a $11.90 million net bullish imbalance.

>>>Click to claim your commission-free cards before trading!

Options Indicators

MRNA’s implied volatility is 101.31%, and with an IV percentile of 95.62%, current option volatility sits in a clearly elevated range, indicating that options are priced expensively versus the stock’s own recent history. Even though the absolute IV is very high, the key takeaway is that implied volatility is near the top end of its historical distribution, so option premiums are rich and volatility expectations are stretched. The Call/Put volume ratio is 1.11, pointing to modestly stronger interest in calls relative to puts.

Large Trades

A CALL combination with a net debit of $11.90 million was the standout large trade, consisting of four long call legs at the $200.00 strike expiring on 2026-11-20. With MRNA referenced at $145.13, all of these calls are out of the money, and the structure is clearly a premium-paid bullish positioning rather than an income trade. Because this was executed as a call combination for a net debit, the strategic intent points to a directional upside bet, seeking meaningful participation if MRNA rallies sharply above the current level over the longer-dated horizon.

Overall large-trade sentiment is decisively bullish, with total bullish flow at $11.90 million versus $0.00 million bearish, for a net bullish imbalance of $11.90 million. The conclusion is straightforward: institutional-sized activity is leaning positive on MRNA, and the fact that the only notable block was a sizable net-debit long call structure reinforces a speculative upside view rather than a hedge or premium-collection stance.

Strategy Reference

For investors not looking to pay rich premiums, an alternative is selling the $80.00 strike put expiring 2026-11-20 to collect elevated IV while maintaining a very low assignment probability given MRNA’s current price above $145.00, or using a bull call spread with the $200.00/$220.00 strikes to cap upfront cost and margin requirements.